个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Combined Immunotherapy for Hepatocellular Carcinoma: How to Maximize Immune Checkpoint Blockade Synergic Anti-tumor Effect

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Huang Yujie[1,2] * ; Zhang Yu[1,2] ; Zhang Mingyu[1,2] ; Zhao Kai[1,2] ; Feng Lina[1,2] ; Guan Jialun[1,2] ; Dong Ruonan[1,2] ; Liu Jingmei[1,2] ; Tian Dean[1,2] ; Liu Mei[1,2] ; Xia Suhong[1,2,*1] ; Liao Jiazhi[1,2,*1] ;
单位： [1]Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, [2]Institute of Liver and Gastrointestinal Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出处：
DOI： 10.1016/j.critrevonc.2023.104070
ISSN：

关键词： Hepatocellular carcinoma Immune checkpoint inhibitors Combination therapy

摘要：
Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer and has an increasing incidence worldwide. The management of HCC still has many restrictions, despite the fact that there are now numerous treatment options, including liver transplantation/resection, locoregional treatments (LRT), and systemic medication. As a turning point in the history of cancer treatment, the discovery of the immune checkpoints and the development of their inhibitors provide new hope for HCC patients. However, limited objective response rate and insignificant overall survival improvement are still urgent problems to be solved for immune checkpoint inhibitors (ICIs). Combination therapies are considered a solution for improving the effectiveness and response rate of ICIs, and several forms of combination treatments are currently being actively researched. In this review, we summarize the mainstream combination strategies, explain their theoretical basis, introduce several important and ongoing clinical trials, and suggest some potential future paths in this area at the conclusion of the review. AVAILABILITY OF DATA AND MATERIALS: Not applicable.Copyright © 2023. Published by Elsevier B.V.

基金：
National Key R&D Program of China (2021YFC2600203).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 2 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 HEMATOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, [2]Institute of Liver and Gastrointestinal Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
通讯作者：
通讯机构： [1]Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, [2]Institute of Liver and Gastrointestinal Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [*1]Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
推荐引用方式(GB/T 7714)：
Huang Yujie,Zhang Yu,Zhang Mingyu,et al.Combined Immunotherapy for Hepatocellular Carcinoma: How to Maximize Immune Checkpoint Blockade Synergic Anti-tumor Effect[J].CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY.2023,189:doi:10.1016/j.critrevonc.2023.104070.
APA：
Huang Yujie,Zhang Yu,Zhang Mingyu,Zhao Kai,Feng Lina...&Liao Jiazhi.(2023).Combined Immunotherapy for Hepatocellular Carcinoma: How to Maximize Immune Checkpoint Blockade Synergic Anti-tumor Effect.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY,189,
MLA：
Huang Yujie,et al."Combined Immunotherapy for Hepatocellular Carcinoma: How to Maximize Immune Checkpoint Blockade Synergic Anti-tumor Effect".CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 189.(2023)

相关文献

[1]Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis [2]基于免疫节点抑制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021版) [3]Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition) [4]免疫检查点抑制剂药物在肝细胞癌治疗中的研究进展 [5]Immune Checkpoint Inhibitors Related to Cardiotoxicity [6]Advances of Targeted Therapy for Hepatocellular Carcinoma [7]Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy [8]CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma [9]Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma [10]Immune checkpoint inhibitors in the treatment of virus-associated cancers

资源点击量：434 今日访问量：0 总访问量：419 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）